Introducing Oncotarget To All

Past few years have been witness to a vast accumulation of knowledge on oncogenes, cellular processes, oncoproteins, tumor suppressors, cellular responses, signal transduction, intercellular interactions along with the function as well as dysfunction of cells, organs, and other systems. In fact, it is the therapeutic targeting of all these molecules as well as processes that have become a growing area in the field of cancer research. This field is becoming increasingly complex as well as multidisciplinary. Hence now the knowledge has to move from basic research and reach the clinic. This would encompass varied fields that would include cell biology, molecular biology, pharmacology, as well as pathology, physiology, oncology and so much more.

Read more https://www.ncbi.nlm.nih.gov/pmc/journals/1558/

Even in many other medical disciplines, new therapy targets have been identified. The agents that have been developed for specific diseases can be used in treating cancer. This can be applied vice versa too. There are some drugs being used for treating infections and such other disorders. These can impact targets that are relevant to cancer too. Download output styles at Endnote.com.

This is the right time for a new journal that will be specifically focused on cancer-relevant targets. It will have to encompass the complexity of this vast field.

Several of the inaugural issues of Oncotarget feature papers on basic, besides translational as well as clinical research. Next are the paradigm-shifting articles. Besides, there would be systematic reviews, along with opinions as well as perspectives coming in from eminent personalities. This way it has a unique as well as broad scope. Oncotarget is offering several other unique features too. Hence it is going to be a high impact journal that is going to make a mark in the twenty-first century.

There are many drugs that can be particularly attractive as anti-cancer agents as they have been approved for clinical use. Hence their effects, as well as side effects, are already known. The anti-malarial, as well as anti-epileptic drugs, are considered as anti-cancer drugs. Now some anti-cancer drugs are also being indicated for atherosclerosis and even aging. Hence oncotarget is going to encompass research on molecules, pathways, as well as cellular functions, cell types along with tissues that can be targeted which are relevant to cancer along with other diseases. Oncotarget is also available on Dove Press.